How to Get Trulicity (Dulaglutide) in Massachusetts

Massachusetts Telehealth Laws and Trulicity Prescribing

Massachusetts permits full prescriptive authority through telehealth for GLP-1 receptor agonists like dulaglutide. A clinician licensed in the Commonwealth can evaluate a patient via synchronous audio-video visit, order labs electronically, and transmit a Trulicity prescription to any in-state or mail-order pharmacy. No in-person visit is required for the initial prescription.

The Massachusetts Board of Registration in Medicine updated its telehealth guidance after the COVID-19 public health emergency, making permanent many of the flexibilities introduced during the pandemic. Nurse practitioners in Massachusetts hold full practice authority under state law, meaning an NP can independently prescribe Trulicity without physician co-signature. Physician assistants may also prescribe under a supervisory agreement with a licensed physician.

Telehealth platforms that serve Massachusetts patients must verify the prescriber holds an active Massachusetts medical license. Out-of-state clinicians cannot prescribe controlled or non-controlled substances to Massachusetts residents unless they also carry a Massachusetts license. This matters for patients comparing national telehealth services: confirm the platform staffs MA-licensed providers before scheduling.

The FDA-approved prescribing information for Trulicity specifies that dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes [1]. It carries a secondary indication for reducing major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established or multiple cardiovascular risk factors.

Who Can Prescribe Trulicity in Massachusetts

Any clinician with prescriptive authority under Massachusetts law can write a Trulicity prescription. That includes MDs, DOs, NPs, and PAs.

Massachusetts is one of 27 states granting nurse practitioners full practice authority, according to the American Association of Nurse Practitioners. This means NPs in the state can evaluate patients, diagnose type 2 diabetes, order HbA1c and metabolic panels, and prescribe dulaglutide without a collaborative agreement [2]. PAs can prescribe under a delegation agreement with a supervising physician, a requirement that does not typically delay the prescription process.

Endocrinologists, primary care physicians, and internal medicine specialists are the most common prescribers. Some obesity medicine specialists also prescribe dulaglutide off-label for weight management, though the on-label weight-loss GLP-1 in the same family is semaglutide (Wegovy), not dulaglutide.

Patients who already have a diagnosis of type 2 diabetes and recent lab work (HbA1c within 90 days) can often complete a telehealth consultation and receive a prescription the same day.

Required Labs Before Starting Trulicity

Prescribers in Massachusetts will order baseline labs before initiating dulaglutide. The standard panel is straightforward.

HbA1c confirms the diabetes diagnosis and establishes a baseline for measuring response. The American Diabetes Association Standards of Care recommend an HbA1c target of <7% for most adults, though individualized targets may range from <6.5% to <8% depending on age, comorbidities, and hypoglycemia risk [3].

Renal function panel (eGFR and serum creatinine) screens for kidney impairment. Dulaglutide does not require dose adjustment for renal impairment, but baseline kidney function informs overall diabetes management. The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg reduced the composite renal outcome by 15% compared to placebo over a median 5.4 years of follow-up (Gerstein et al., Lancet 2019) [4].

Lipid panel and hepatic function tests round out the metabolic snapshot. These results help the prescriber assess cardiovascular risk and rule out hepatic contraindications for concomitant medications.

A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) is a contraindication to dulaglutide use. Prescribers should ask about thyroid cancer history before writing the prescription.

MassHealth and Commercial Insurance Coverage

MassHealth (Massachusetts Medicaid) covers Trulicity for type 2 diabetes with prior authorization. The PA process verifies the diagnosis, confirms that the patient has tried or has a contraindication to metformin, and documents the clinical rationale for a GLP-1 receptor agonist.

Most commercial insurers in Massachusetts, including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim, and Tufts Health Plan, also cover Trulicity on their formularies. Coverage tiers vary. Some plans place Trulicity on a preferred brand tier (Tier 3) while others classify it as non-preferred brand (Tier 4), which raises the copay.

The prior authorization process typically requires:

• A confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x)
• Documentation of HbA1c level
• Evidence that metformin was tried, is contraindicated, or is not tolerated
• The prescriber's rationale for choosing dulaglutide over other covered GLP-1 options

Processing time ranges from 24 to 72 hours for electronic submissions. Some insurers offer real-time PA through electronic prior authorization (ePA) platforms integrated with electronic health records, which can return a decision within minutes.

Eli Lilly offers the Trulicity Savings Card for commercially insured patients, which can reduce out-of-pocket costs [1]. Patients on government insurance (MassHealth, Medicare Part D) are not eligible for manufacturer copay cards but may qualify for Lilly's patient assistance program if they meet income criteria.

Pharmacy Options in Massachusetts

Massachusetts patients can fill a Trulicity prescription at any retail pharmacy, specialty pharmacy, or licensed mail-order pharmacy. The state also licenses 503A compounding pharmacies that can compound medications under specific conditions.

Retail pharmacies (CVS, Walgreens, Rite Aid, independent pharmacies) stock brand-name Trulicity. Supply has been stable for dulaglutide; it has not experienced the same shortage pressures as semaglutide (Ozempic/Wegovy). Most retail pharmacies can fill the prescription within 1 to 2 business days.

Specialty pharmacies handle Trulicity for patients whose insurance requires specialty pharmacy dispensing. Some plans mandate that injectable medications be filled through a designated specialty pharmacy. Patients should check their plan's requirements.

503A compounding pharmacies in Massachusetts are licensed by the Massachusetts Board of Registration in Pharmacy. These pharmacies can compound patient-specific prescriptions when a prescriber determines a clinical need, such as a dose not commercially available or an allergy to an inactive ingredient. Compounded dulaglutide is not common, as the branded product comes in five dose strengths (0.75 mg, 1.5 mg, 3 mg, and 4.5 mg), but the option exists under state law.

Mail-order pharmacies offer the convenience of home delivery. For a once-weekly injection like Trulicity, a 90-day supply (12 to 13 pens) shipped quarterly can reduce pharmacy trips. Cold-chain shipping is standard for GLP-1 medications, and reputable mail-order pharmacies use insulated packaging with gel packs.

Dulaglutide Dosing and Titration Schedule

Trulicity is initiated at 0.75 mg once weekly. After at least 4 weeks, the dose can be increased to 1.5 mg weekly if additional glycemic control is needed.

The AWARD-11 trial (N=1,842) demonstrated that higher doses of dulaglutide (3 mg and 4.5 mg) provided greater HbA1c reductions than 1.5 mg [5]. At 36 weeks, the 4.5 mg dose reduced HbA1c by 1.87% from baseline versus 1.53% for the 1.5 mg dose. Body weight reductions were also greater with the higher doses: 4.0 kg with 4.5 mg versus 3.0 kg with 1.5 mg.

The titration path:

• Weeks 1 through 4: 0.75 mg weekly
• Week 5 onward: increase to 1.5 mg weekly if HbA1c target not met
• After 4+ weeks at 1.5 mg: may increase to 3 mg weekly
• After 4+ weeks at 3 mg: may increase to maximum 4.5 mg weekly

Each dose step uses a separate pen device. The Trulicity pen is a single-use, pre-filled auto-injector with a hidden needle. Patients inject into the abdomen, thigh, or upper arm, rotating injection sites weekly.

Storage: unopened pens belong in the refrigerator (36 to 46°F). A pen can be kept at room temperature (up to 86°F) for up to 14 days. Do not freeze.

Cardiovascular and Renal Benefits of Dulaglutide

The REWIND trial is the landmark cardiovascular outcomes study for dulaglutide. It enrolled 9,901 participants with type 2 diabetes across 24 countries over a median follow-up of 5.4 years (Gerstein et al., Lancet 2019) [4].

Results showed that dulaglutide 1.5 mg reduced the composite MACE endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 12% compared to placebo (HR 0.88 to 95% CI 0.79 to 0.99, P=0.026). This makes Trulicity one of three GLP-1 receptor agonists with proven cardiovascular benefit, alongside liraglutide (LEADER trial) and semaglutide (SUSTAIN-6 trial).

REWIND was distinctive because 69% of participants had no prior cardiovascular event at enrollment. This is a primary prevention population, not the secondary prevention cohort seen in most prior GLP-1 cardiovascular trials. The finding suggests dulaglutide's cardiovascular protection extends to lower-risk patients with type 2 diabetes.

The renal sub-analysis showed a 15% reduction in the composite renal outcome, driven primarily by a reduction in new-onset macroalbuminuria. The 2024 ADA Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes and atherosclerotic cardiovascular disease, independent of HbA1c [3].

Dr. Hertzel Gerstein, the lead investigator of REWIND, stated: "The results show that dulaglutide reduces cardiovascular events in a broad population of people with type 2 diabetes, including those without prior cardiovascular disease."

Prior Authorization in Massachusetts: Step by Step

Prior authorization for Trulicity in Massachusetts follows a predictable sequence. Knowing the process helps avoid delays.

Step 1: Clinical documentation. The prescriber records the type 2 diabetes diagnosis, current HbA1c, and medication history in the patient's chart. A recent HbA1c (within 90 days) is standard. Most PA forms ask for the specific HbA1c value.

Step 2: Formulary check. The prescriber or pharmacy benefits team verifies the patient's formulary. If dulaglutide is covered but requires PA, the process moves to step 3. If it is not covered, the prescriber may need to submit an exception request or choose an alternative GLP-1.

Step 3: PA submission. The prescriber's office submits the PA request, usually electronically. The submission includes the diagnosis, prior medication trials (specifically metformin), the reason metformin alone is insufficient, and the clinical rationale for dulaglutide.

Step 4: Insurer review. Massachusetts insurers must respond to standard PA requests within 2 business days for non-urgent requests, per state regulation. Urgent requests require a response within 24 hours. MassHealth follows similar timelines.

Step 5: Approval or appeal. If approved, the PA is valid for 12 months with most plans. If denied, the prescriber can file a peer-to-peer review or a formal appeal. Massachusetts law gives patients the right to an external review through the state's Office of Patient Protection if the internal appeal is denied.

The Massachusetts Division of Insurance mandates transparency in PA criteria, and patients can request a copy of the coverage determination criteria from their insurer [6].

Transferring a Trulicity Prescription to Massachusetts

Patients relocating to Massachusetts can transfer an existing Trulicity prescription. The process depends on how the original prescription was written.

If the prescription is at an out-of-state retail pharmacy, a Massachusetts pharmacy can contact the originating pharmacy to request a transfer. Massachusetts accepts prescription transfers from all 50 states for non-controlled substances. Dulaglutide is not a controlled substance, so the transfer is straightforward.

If the patient's prescriber is not licensed in Massachusetts, a new evaluation with an MA-licensed provider is required for refills. Telehealth makes this simple: a follow-up visit documenting the existing diagnosis and stable dose can be completed in 15 to 20 minutes. Bring recent lab work and a medication list.

Insurance may also change with the move. Patients switching from an out-of-state plan to a Massachusetts plan should verify Trulicity coverage on the new formulary before running out of medication. A 30-day bridge supply can often be obtained through emergency prescription provisions at Massachusetts pharmacies.

How Long Until You Receive Trulicity in Massachusetts

The timeline from initial consultation to first injection depends on two variables: prior authorization turnaround and pharmacy fulfillment.

Without PA required (cash pay or PA-exempt plans): a prescription submitted after a morning telehealth visit can be ready at a retail pharmacy the same day or next business day. Mail-order delivery adds 3 to 5 business days.

With PA required: add 1 to 3 business days for the insurer's review. In total, patients with PA-requiring plans should expect 3 to 7 business days from the initial visit to medication in hand.

Expedited pathways exist. Some telehealth platforms submit the PA concurrently with the consultation, cutting the total time. Certain plans offer real-time ePA, which returns a decision within minutes during the pharmacy transaction.

Patients with an HbA1c above 10% or symptomatic hyperglycemia may qualify for an urgent PA, which Massachusetts insurers must process within 24 hours.

Common Side Effects and Monitoring

The most frequent side effects of dulaglutide are gastrointestinal: nausea (12.4%), diarrhea (8.9%), vomiting (6.0%), abdominal pain (6.5%), and decreased appetite (4.9%) [1]. These effects are dose-dependent and typically diminish over the first 4 to 8 weeks of treatment.

The REWIND investigators reported that 8.6% of dulaglutide-treated patients discontinued due to gastrointestinal adverse events, compared to 3.5% in the placebo group (Gerstein et al., Lancet 2019) [4]. Slow dose titration reduces the incidence and severity of nausea.

Massachusetts prescribers will typically schedule a follow-up visit (telehealth or in-person) at 4 to 6 weeks after initiation. Monitoring includes:

• HbA1c at 3 months to assess glycemic response
• Renal function panel at 3 to 6 months
• Assessment of GI tolerability and injection technique
• Weight measurement and blood pressure

The Endocrine Society clinical practice guideline on pharmacologic treatment of type 2 diabetes recommends GLP-1 receptor agonists as second-line therapy after metformin, or as first-line therapy in patients with atherosclerotic cardiovascular disease [7].

Dr. Vanita Aroda, a principal investigator in multiple AWARD trials, has noted: "Dulaglutide's once-weekly dosing and auto-injector design make it particularly well-suited for patients who are new to injectable therapy."